Abstract | AIMS: METHODS AND RESULTS: Patients presenting with ST-segment elevation anterior AMI were randomized to receive placebo vs. adenosine (50 or 70 microg/kg/min) for 3 h starting within 15 min of reperfusion therapy. In the present post hoc hypothesis generating study, the results were stratified according to the timing of reperfusion, i.e. > or = or < the median 3.17 h, and by reperfusion modality. In patients receiving reperfusion < 3.17 h, adenosine compared with placebo significantly reduced 1-month mortality (5.2 vs. 9.2%, respectively, P = 0.014), 6-month mortality (7.3 vs. 11.2%, P = 0.033), and the occurrence of the primary 6-month composite clinical endpoint of death, in-hospital CHF, or rehospitalization for CHF at 6 months (12.0 vs. 17.2%, P = 0.022). Patients reperfused beyond 3 h did not benefit from adenosine. CONCLUSION: In this post hoc analysis, 3 h adenosine infusion administered as an adjunct to reperfusion therapy within the first 3.17 h onset of evolving anterior ST-segment elevation AMI enhanced early and late survival, and reduced the composite clinical endpoint of death or CHF at 6 months.
|
Authors | Robert A Kloner, Mervyn B Forman, Raymond J Gibbons, Allan M Ross, R Wayne Alexander, Gregg W Stone |
Journal | European heart journal
(Eur Heart J)
Vol. 27
Issue 20
Pg. 2400-5
(Oct 2006)
ISSN: 0195-668X [Print] England |
PMID | 16782719
(Publication Type: Journal Article, Multicenter Study, Randomized Controlled Trial)
|
Chemical References |
- Vasodilator Agents
- Adenosine
|
Topics |
- Adenosine
(therapeutic use)
- Angioplasty, Balloon, Coronary
(mortality)
- Double-Blind Method
- Female
- Hospital Mortality
- Humans
- Male
- Middle Aged
- Myocardial Infarction
(mortality, therapy)
- Myocardial Reperfusion
(methods, mortality)
- Recurrence
- Thrombolytic Therapy
(mortality)
- Time Factors
- Treatment Outcome
- Vasodilator Agents
(therapeutic use)
|